Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
|Articles|August 2, 2012
- Pharmaceutical Technology-08-02-2012
- Volume 36
- Issue 8
Pharmaceutical Technology, August 2012 Issue (PDF)
Measuring Growth - Big Pharma's Manufacturing Investments
Advertisement
Articles in this issue
over 14 years ago
Q&A with Babu Padmanabhan, STEER Engineeringover 14 years ago
The Truth About Drug Shortagesover 14 years ago
Report from Japanover 14 years ago
Pharmaceutical-Based Cargo Security and Theft Preventionover 14 years ago
Scaling up API Synthesesover 14 years ago
Small Changes, System-Wide Impactover 14 years ago
Measuring Growth in Big Pharma's Manufacturing Investmentover 14 years ago
Gauging Biopharm Outsourcingover 14 years ago
In the Spotlight August 2012over 14 years ago
FDA User-Fee Legislation Sets Stage for ChangeAdvertisement
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
5